Dewpoint Therapeutics restructures to ‘make room’ for entry into the clinic next year in oncology, ALS

Con­den­sate mod­u­la­tor start­up Dew­point Ther­a­peu­tics is go­ing through a re­struc­tur­ing as it gears up for its first clin­i­cal tri­als next year in col­orec­tal can­cer and amy­otroph­ic lat­er­al scle­ro­sis, CEO Ameet Nath­wani told End­points News.

The biotech will let go 18 po­si­tions, about 15% of its staff, as it tran­si­tions from a dis­cov­ery-stage start­up to a drug de­vel­op­ment com­pa­ny, Nath­wani said in an in­ter­view on Wednes­day morn­ing. STAT News first re­port­ed the moves Tues­day af­ter­noon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.